Genenta Science S.p.A. (GNTA) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Milan, MI, Italy. 현재 CEO는 Pierluigi Paracchi.
GNTA 을(를) 보유 IPO 날짜 2021-12-15, 13 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $12.28M.
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
